ABIOMED Stock News

NEW YORK, Nov. 29, 2021 /PRNewswire/ -- Technavio''s latest offering, the Ventricular Assist Devices Market report provides a detailed analysis of the competitive scenario and the market growth across various regions. The ventricular assist devices market value is set to grow by USD 4.05

State of Alaska Department of Revenue lowered its position in Abiomed, Inc. (NASDAQ:ABMD) by 0.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 27,219 shares of the medical equipment providers stock after selling 167 shares during the period. State of []

Abiomed (NASDAQ:ABMD) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Wednesday, Zacks.com reports. The firm presently has a $369.00 target price on the medical equipment provider’s stock. Zacks Investment Research‘s price target indicates a potential upside of 7.42% from the company’s previous close. According […]

Abiomed, Inc. (NASDAQ:ABMD) has earned an average recommendation of Hold from the six analysts that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company. The average twelve-month target price among []

Abiomed's (ABMD) CEO Mike Minogue on Q2 2022 Results - Earnings Call Transcript

Abiomed (ABMD) delivered earnings and revenue surprises of 5.10% and -0.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Abiomed (ABMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Investors continue to be optimistic about Abiomed (ABMD) owing to its strength in the Impella product line.

Abiomed's strong growth drivers and advanced product pipeline will boost its long-term revenue growth. The company's Impella range of micro heart pumps will continue to see increasing adoption globall

Abiomed's (ABMD) Impella ECP is likely to offer critical hemodynamic support to a wider pool of coronary artery disease patients.

The FDA has granted breakthrough device designation to Abiomed Inc's (NASDAQ: ABMD) Impella ECP expandable percutaneous heart pump. Abiomed designed the Impella ECP heart pump to be compatible wit

DANVERS, Mass.--(BUSINESS WIRE)--The U.S. Food and Drug Administration has granted breakthrough device designation to Abiomed's Impella ECP expandable percutaneous heart pump.

Investors continue to be optimistic about Abiomed (ABMD) owing to its strength in the Impella product line.

Abiomed's (ABMD) strength in Impella product revenues drives its Q1 top line.

Abiomed, Inc. (ABMD) CEO Mike Minogue on Q1 2022 Results - Earnings Call Transcript